Last reviewed · How we verify
NCT05167266: COV-COG
Long-Covid: Treatment of Cognitive Difficulties
Completed
NA
Last updated 9 July 2024
What this trial tests
NA trial testing Psychoeducation in COVID-19 in 130 participants. Completed in 2 July 2024.
Timeline
15 March 2022
Primary endpoint
26 January 2024
26 January 2024
2 July 2024
Quick facts
| Lead sponsor | University of Liege |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 130 |
| Start date | 15 March 2022 |
| Primary completion | 26 January 2024 |
| Estimated completion | 2 July 2024 |
| Sites | 5 locations across Belgium |
Drugs / interventions tested
- Psychoeducation
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Cognitive Dysfunction — all drugs for Cognitive Dysfunction →
Sponsor
University of Liege
Who can join
Adults 18 to 70, any sex, with COVID-19 or Cognitive Dysfunction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to explore the potential effectiveness of two common low-dose interventions, one targeting cognitive difficulties and the other targeting affective difficulties on quality of life and cognition in people suffering from long-COVID with cognitive complaints.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Post-COVID cognitive dysfunction: current status and research recommendations for high risk population.
Quan M, Wang X, Gong M, Wang Q, et al · · 2023 · cited 62× · PMID 37457901 · DOI 10.1016/j.lanwpc.2023.100836 -
Interventions for mental health, cognition, and psychological wellbeing in long COVID: a systematic review of registered trials.
Hawke LD, Nguyen ATP, Ski CF, Thompson DR, et al · · 2022 · cited 45× · PMID 35768406 · DOI 10.1017/s0033291722002203 -
COVCOG: Immediate and long-term cognitive improvement after cognitive versus emotion management psychoeducation programs - a randomized trial in covid patients with neuropsychological difficulties.
Willems S, Didone V, Cabello Fernandez C, Delrue G, et al · · 2023 · cited 5× · PMID 37596541 · DOI 10.1186/s12883-023-03346-9 -
Profiles of Individuals With Long COVID Reporting Persistent Cognitive Complaints.
Cabello Fernandez C, Didone V, Slama H, Dupuis G, et al · · 2025 · cited 3× · PMID 40645608 · DOI 10.1093/arclin/acaf064 -
Cognitive and affective psychoeducation for Long COVID: a randomized controlled trial.
Cabello Fernandez C, Didone V, Lesoinne A, Slama H, et al · · 2025 · cited 1× · PMID 41277895 · DOI 10.1093/braincomms/fcaf447
Verify or expand the search:
- PubMed search for NCT05167266
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Psychoeducation
Trials testing the same drug.
- NCT07227987 — Cognitive Rehabilitation for Treatment of Anger in Veterans With TBI and PTSD · NA · not yet recruiting
- NCT06755827 — Pilot Testing a Novel Approach to Pediatric Obesity Treatment · Phase 1, PHASE2 · recruiting
- NCT07129369 — Effects of a Peer-facilitated, Acceptance-based Self-learning for Illness Management (PASIM) Program · NA · not yet recruiting
- NCT06972368 — Home-Based tDCS for Depression in BPD · NA · recruiting
- NCT06815692 — Interdisciplinary Interventions After mTBI · not yet recruiting
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other University of Liege trials
Trials by the same sponsor.
- NCT07523178 — Effects of a Targeted Prevention Program on Change-of-Direction Biomechanics and Performance in Elite Female Soccer Play · NA · not yet recruiting
- NCT07472400 — Mobility, Strength, and Functional Outcomes Before Surgery, at 3 Months, and at 6 Months After Hip Arthroscopy for Femor · not yet recruiting
- NCT07331779 — Effect of tDCS Timing on Motor Recovery in Acute Stroke Rehabilitation · NA · not yet recruiting
- NCT07237893 — Impact of a Physical Activity Intervention on Cardiometabolic Health, Mental Health, and Lifestyle Factors. · NA · not yet recruiting
- NCT06964282 — Iliopsoas (IPB) and Pericapsular Nerve Group (PENG) Blocks Comparison on Analgesia and Recovery After Total Hip Arthropl · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05167266 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Liege
- Last refreshed: 9 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05167266.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing